ACTM-838
- Generic Name
- ACTM-838
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Actym Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06336148
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, 5115 Centre Ave, Pittsburgh, Pennsylvania, United States
🇦🇺Alfred Hospital, 55 Commercial Road, Site No: 201, Melbourne, Victoria, Australia
🇺🇸University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave., Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath